Nathan Yakubu Shehu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nathan Yakubu Shehu has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
David Shwe
Department of Paediatrics, Jos University Teaching Hospital, Jos, Nigeria
3 shared publications- Adebola Tolulope Olayinka
World Health Organization - Nigeria
2 shared publications Chikwe Ihekweazu
Affiliations Nigeria COVID-19 Research Coalition, Abuja, Nigeria, World Health Organization Hub for Pandemic and Epidemic Intelligence, Berlin, Germany
2 shared publicationsChristopher Sabo Yilgwan
Department of Paediatrics, Jos University Teaching Hospital, Jos, Nigeria
2 shared publications- Dung Davou Pam
University of Jos
2 shared publications - Filibus Danjuma Dami
Department of Zoology, Faculty of Natural Sciences, University of Jos, Nigeria; AP Leventis Ornithological Research Institute, Laminga, Plateau State, Nigeria
2 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Annals of Tropical Research, Visayas State University in Annals of Tropical Research
- Vol. 48 (1) , 4-17
Geospatial Distribution of Dengue Virus (DENV) Vectors in Some Communities of Plateau State, Nigeria
Background: Emerging infectious diseases have persisted due to increased human migration and global warming. Mosquito-borne arboviral infections are of primary concern due to their complex vector dynamics and significant public health burden. However, there is limited data on the geospatial distribution of dengue virus vectors in Plateau State, Nigeria, limiting evidence-based vector surveillance and control strategies. Objectives: This study assessed the geospatial distribution of dengue virus vectors across some communities in Plateau State, Nigeria. Methods: Larval mosquito samples were collected for three months (May-July 2023) from different habitats, using dip methods. Collected mosquitoes were reared to adult and identified morphologically. Result: A total of 4082 Aedes mosquitoes, comprising only two species, were collected: Aedes aegypti (4074; 99.8%) and Aedes vitattus (8; 0.2%). Jos South recorded the highest mosquito abundance (1810; 44.34%), with the lowest in Pankshin (178; 4.36%) (p < .05). Five breeding habitats were encountered, with more mosquitoes encountered in car tires 2210 (54.14%) and containers 1038 (25.43%) (p < .05). Overall breeding index was: House Index = 50.96 (95% CI: 43.11-58.80), Container Index = 45.43 (95% CI: 39.17-51.69), and Breteau Index = 42.16% (95% CI: 36.04-48.27). Conclusion: Aedes mosquitoes are actively breeding in the area and although the breeding indices are similar across locations, they portend a high risk of arboviral disease transmission in the event of an outbreak. This could also be facilitated by the spatial distribution of the vectors and their breeding activities in the place. Effective control measures aimed at reducing the breeding habitats of these vectors are therefore encouraged in Plateau State.
- 14 May 2026
- Published by Annals of Tropical Research, Visayas State University in Annals of Tropical Research
- Vol. 48 (1) , 4-17
Open AccessGeospatial Distribution of Dengue Virus (DENV) Vectors in Some Communities of Plateau State, Nigeria
Background: Emerging infectious diseases have persisted due to increased human migration and global warming. Mosquito-borne arboviral infections are of primary concern due to their complex vector dynamics and significant public health burden. However, there is limited data on the geospatial distribution of dengue virus vectors in Plateau State, Nigeria, limiting evidence-based vector surveillance and control strategies. Objectives: This study assessed the geospatial distribution of dengue virus vectors across some communities in Plateau State, Nigeria. Methods: Larval mosquito samples were collected for three months (May-July 2023) from different habitats, using dip methods. Collected mosquitoes were reared to adult and identified morphologically. Result: A total of 4082 Aedes mosquitoes, comprising only two species, were collected: Aedes aegypti (4074; 99.8%) and Aedes vitattus (8; 0.2%). Jos South recorded the highest mosquito abundance (1810; 44.34%), with the lowest in Pankshin (178; 4.36%) (p < .05). Five breeding habitats were encountered, with more mosquitoes encountered in car tires 2210 (54.14%) and containers 1038 (25.43%) (p < .05). Overall breeding index was: House Index = 50.96 (95% CI: 43.11-58.80), Container Index = 45.43 (95% CI: 39.17-51.69), and Breteau Index = 42.16% (95% CI: 36.04-48.27). Conclusion: Aedes mosquitoes are actively breeding in the area and although the breeding indices are similar across locations, they portend a high risk of arboviral disease transmission in the event of an outbreak. This could also be facilitated by the spatial distribution of the vectors and their breeding activities in the place. Effective control measures aimed at reducing the breeding habitats of these vectors are therefore encouraged in Plateau State.
- 25 November 2025
- Published by Elsevier in The Veterinary Journal
- Vol. 315, 106506
Molecular detection of Torque teno sus virus from domestic pigs in North Central, Nigeria, 2022–2023
- 25 November 2025
- Published by Elsevier in The Veterinary Journal
- Vol. 315, 106506
Molecular detection of Torque teno sus virus from domestic pigs in North Central, Nigeria, 2022–2023
- Open Access
- 3 April 2025
- Vol. 66 (1) , 357-363
Is there Co-infection of Influenza and Covid-19 in Jos, North Central Nigeria?
Influenza virus and severe acute respiratory syndrome virus-2 (SARS CoV-2) are known to cause respiratory disease in humans that may be fatal. They have caused epidemics and constitute significant public health challenges because of their ability to spread and cause severe disease. Co-infection with both viruses has been shown to increase the odds of fatality among affected patients. Our study aimed to investigate co-infection with influenza among patients with coronavirus disease-2019 (COVID-19) in Jos, Plateau State. We carried out a cross-sectional study using stored nasopharyngeal and oropharyngeal samples of patients diagnosed with COVID-19 using GeneXpert. The samples were collected at our institution and stored at −80 °C. The samples were analysed for influenza co-infection using real-time reverse transcriptase polymerase chain reaction. Two-hundred-and-forty-one (241) stored samples of patients diagnosed with COVID-19 were analysed. None of the samples tested positive for the influenza virus. We found no case of influenza and SARS-CoV-2 co-infection among the patients studied. This suggests that the prevalence of influenza virus infection may be low in our setting and partly explains the relatively benign outcome of SARS-CoV-2 infections in our region.
- 3 April 2025
- Vol. 66 (1) , 357-363
Open AccessIs there Co-infection of Influenza and Covid-19 in Jos, North Central Nigeria?
Influenza virus and severe acute respiratory syndrome virus-2 (SARS CoV-2) are known to cause respiratory disease in humans that may be fatal. They have caused epidemics and constitute significant public health challenges because of their ability to spread and cause severe disease. Co-infection with both viruses has been shown to increase the odds of fatality among affected patients. Our study aimed to investigate co-infection with influenza among patients with coronavirus disease-2019 (COVID-19) in Jos, Plateau State. We carried out a cross-sectional study using stored nasopharyngeal and oropharyngeal samples of patients diagnosed with COVID-19 using GeneXpert. The samples were collected at our institution and stored at −80 °C. The samples were analysed for influenza co-infection using real-time reverse transcriptase polymerase chain reaction. Two-hundred-and-forty-one (241) stored samples of patients diagnosed with COVID-19 were analysed. None of the samples tested positive for the influenza virus. We found no case of influenza and SARS-CoV-2 co-infection among the patients studied. This suggests that the prevalence of influenza virus infection may be low in our setting and partly explains the relatively benign outcome of SARS-CoV-2 infections in our region.
- Open Access
- 15 July 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1395939
Double stigma: a cross-sectional study of Lassa patients with hearing loss in North Central Nigeria
Introduction: Lassa fever is a zoonotic infectious disease endemic in West Africa with a high case-fatality rate and reported stigmatization of surviving patients. This study examines discrimination among survivors of Lassa fever (LF) complicated by hearing loss (HL).Methods: This cross-sectional qualitative study used an in-depth interview guide to collect information from patients with HL about their experience of stigma. Interviews were conducted by a trained team of interviewers at the Jos University Teaching Hospital between January and April 2022 in Hausa language after informed consent was obtained. Recordings of the interviews were transcribed and translated from Hausa to English. Data analysis was conducted using NVivo software using a thematic framework approach.Results: Most (73%) respondents were male (n = 11); 27% were female (n = 4). The median age was 35 years (interquartile range, 16.5). Some Lassa fever patients experienced stigma and discrimination (53%) including isolation and withdrawal of family and community support during and after illness. HL increased stigma, as some patients were labeled “deaf” by other community members, increasing perceived stigma and devaluation. HL affected the socio-economic wellbeing of some who could not communicate well with their families and customers and constrained social interactions, evoking pain and apathy. Some survivors of LF and victims of its sequelae of HL experienced double stigmatization. While they were ill with LF, a third of respondents reported avoidance and isolation by family and community members who withdrew care and support both to them and their close family members. These forms of stigmatization strained their relationships.Conclusion: There is a need to address stigma in LF survivors who develop HL through concerted community-owned awareness to improve their quality of life along with a robust social support system to aid prevention.
- 15 July 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1395939
Open AccessDouble stigma: a cross-sectional study of Lassa patients with hearing loss in North Central Nigeria
Introduction: Lassa fever is a zoonotic infectious disease endemic in West Africa with a high case-fatality rate and reported stigmatization of surviving patients. This study examines discrimination among survivors of Lassa fever (LF) complicated by hearing loss (HL).Methods: This cross-sectional qualitative study used an in-depth interview guide to collect information from patients with HL about their experience of stigma. Interviews were conducted by a trained team of interviewers at the Jos University Teaching Hospital between January and April 2022 in Hausa language after informed consent was obtained. Recordings of the interviews were transcribed and translated from Hausa to English. Data analysis was conducted using NVivo software using a thematic framework approach.Results: Most (73%) respondents were male (n = 11); 27% were female (n = 4). The median age was 35 years (interquartile range, 16.5). Some Lassa fever patients experienced stigma and discrimination (53%) including isolation and withdrawal of family and community support during and after illness. HL increased stigma, as some patients were labeled “deaf” by other community members, increasing perceived stigma and devaluation. HL affected the socio-economic wellbeing of some who could not communicate well with their families and customers and constrained social interactions, evoking pain and apathy. Some survivors of LF and victims of its sequelae of HL experienced double stigmatization. While they were ill with LF, a third of respondents reported avoidance and isolation by family and community members who withdrew care and support both to them and their close family members. These forms of stigmatization strained their relationships.Conclusion: There is a need to address stigma in LF survivors who develop HL through concerted community-owned awareness to improve their quality of life along with a robust social support system to aid prevention.
- Open Access
- 15 July 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (7) , e0003371
Performance evaluation of SARS-CoV-2 rapid diagnostic tests in Nigeria: A cross-sectional study
The COVID-19 pandemic challenged health systems globally. Reverse transcription polymerase chain reaction (RT-PCR) is the gold standard for detecting the presence of SARS-CoV-2 in clinical samples. Rapid diagnostic test (RDT) kits for COVID-19 have been widely used in Nigeria. This has greatly improved test turnover rates and significantly decreased the high technical demands of RT-PCR. However, there is currently no nationally representative evaluation of the performance characteristics and reliability of these kits. This study assessed the sensitivity, specificity, and predictive values of ten RDT kits used for COVID-19 testing in Nigeria. This large multi-centred cross-sectional study was conducted across the 6 geo-political zones of Nigeria over four months. Ten antigen (Ag) and antibody (Ab) RDT kits were evaluated, and the results were compared with RT-PCR. One thousand, three hundred and ten (1,310) consenting adults comprising 767 (58.5%) males and 543 (41.5%) females participated in the study. The highest proportion, 757 (57.7%), were in the 20–39 years’ age group. In terms of diagnostic performance, Lumira Dx (61.4, 95% CI: 52.4–69.9) had the highest sensitivity while MP SARS and Panbio (98.5, 95% CI: 96.6–99.5) had the highest specificity. For predictive values, Panbio (90.7, 95% CI: 79.7–96.9) and Lumira Dx (81.2, 95% CI: 75.9–85.7) recorded the highest PPV and NPV respectively. Ag-RDTs had better performance characteristics compared with Ab-RDTs; however, the sensitivities of all RDTs in this study were generally low. The relatively high specificity of Ag-RDTs makes them useful for the diagnosis of infection in COVID-19 suspected cases where positive RDT may not require confirmation by molecular testing. There is therefore the need to develop RDTs in-country that will take into consideration the unique environmental factors, interactions with other infectious agents, and strains of the virus circulating locally. This may enhance the precision of rapid and accurate diagnosis of COVID-19 in Nigeria.
- 15 July 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (7) , e0003371
Open AccessPerformance evaluation of SARS-CoV-2 rapid diagnostic tests in Nigeria: A cross-sectional study
The COVID-19 pandemic challenged health systems globally. Reverse transcription polymerase chain reaction (RT-PCR) is the gold standard for detecting the presence of SARS-CoV-2 in clinical samples. Rapid diagnostic test (RDT) kits for COVID-19 have been widely used in Nigeria. This has greatly improved test turnover rates and significantly decreased the high technical demands of RT-PCR. However, there is currently no nationally representative evaluation of the performance characteristics and reliability of these kits. This study assessed the sensitivity, specificity, and predictive values of ten RDT kits used for COVID-19 testing in Nigeria. This large multi-centred cross-sectional study was conducted across the 6 geo-political zones of Nigeria over four months. Ten antigen (Ag) and antibody (Ab) RDT kits were evaluated, and the results were compared with RT-PCR. One thousand, three hundred and ten (1,310) consenting adults comprising 767 (58.5%) males and 543 (41.5%) females participated in the study. The highest proportion, 757 (57.7%), were in the 20–39 years’ age group. In terms of diagnostic performance, Lumira Dx (61.4, 95% CI: 52.4–69.9) had the highest sensitivity while MP SARS and Panbio (98.5, 95% CI: 96.6–99.5) had the highest specificity. For predictive values, Panbio (90.7, 95% CI: 79.7–96.9) and Lumira Dx (81.2, 95% CI: 75.9–85.7) recorded the highest PPV and NPV respectively. Ag-RDTs had better performance characteristics compared with Ab-RDTs; however, the sensitivities of all RDTs in this study were generally low. The relatively high specificity of Ag-RDTs makes them useful for the diagnosis of infection in COVID-19 suspected cases where positive RDT may not require confirmation by molecular testing. There is therefore the need to develop RDTs in-country that will take into consideration the unique environmental factors, interactions with other infectious agents, and strains of the virus circulating locally. This may enhance the precision of rapid and accurate diagnosis of COVID-19 in Nigeria.
- Open Access
- 25 April 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (4) , e0000685
Analysis of sensorineural hearing loss in patients attending an otolaryngology clinic in North Central Nigeria
Hearing loss is the third leading cause of years lived with disability. Approximately 1.4 billion people have hearing loss, of which 80% reside in low- and middle-income countries with limited audiology and otolaryngology care available to them. The objective of this study was to estimate period prevalence of hearing loss and audiogram patterns of patients attending an otolaryngology clinic in North Central Nigeria. A 10-year retrospective cohort study was carried out analyzing 1507 patient records of pure tone audiograms of patients at the otolaryngology clinic at Jos University Teaching Hospital, Plateau State, Nigeria. Prevalence of hearing loss of moderate or higher grade increased significantly and steadily after age 60. Compared to other studies, there was a higher prevalence of overall sensorineural hearing loss (24–28% in our study compared to 1.7–8.4% globally) and higher proportions of the flat audiogram configuration among the younger age patients (40% in younger patients compared to 20% in patients older than 60 years). The higher prevalence of the flat audiogram configuration compared to other parts of the world may be suggestive of an etiology specific to this region, such as the endemic Lassa Fever and Lassa virus infection in addition to cytomegalovirus or other viral infections associated with hearing loss.
- 25 April 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (4) , e0000685
Open AccessAnalysis of sensorineural hearing loss in patients attending an otolaryngology clinic in North Central Nigeria
Hearing loss is the third leading cause of years lived with disability. Approximately 1.4 billion people have hearing loss, of which 80% reside in low- and middle-income countries with limited audiology and otolaryngology care available to them. The objective of this study was to estimate period prevalence of hearing loss and audiogram patterns of patients attending an otolaryngology clinic in North Central Nigeria. A 10-year retrospective cohort study was carried out analyzing 1507 patient records of pure tone audiograms of patients at the otolaryngology clinic at Jos University Teaching Hospital, Plateau State, Nigeria. Prevalence of hearing loss of moderate or higher grade increased significantly and steadily after age 60. Compared to other studies, there was a higher prevalence of overall sensorineural hearing loss (24–28% in our study compared to 1.7–8.4% globally) and higher proportions of the flat audiogram configuration among the younger age patients (40% in younger patients compared to 20% in patients older than 60 years). The higher prevalence of the flat audiogram configuration compared to other parts of the world may be suggestive of an etiology specific to this region, such as the endemic Lassa Fever and Lassa virus infection in addition to cytomegalovirus or other viral infections associated with hearing loss.
- Open Access
- 27 March 2023
- Published by Veterinary World in International Journal of One Health
- Vol. 9 (1) , 10-14
One Health epidemic preparedness: Biosafety quality improvement training in Nigeria
Background and Aim: One of the key components of the O ne Health approach to epidemic preparedness is raising awareness and increasing the knowledge of emerging infectious diseases, prevention, and risk reduction. However, related research can involve significant risks to biosafety and biosecurity. For this purpose, we organized a multidisciplinary biosafety hands-on workshop to inform and increase the knowledge of infectious diseases and risk mitigation. This study aimed to describe the process and outcome of a hands-on biosafety training program using a One Health a pproach across a multidisciplinary and multi-specialty group in Nigeria. Materials and Methods: A face-to-face hands-on training for 48 participants was organized by the West African Center for Emerging Infectious Diseases (WAC-EID) at the Jos University Teaching Hospital, serving as a lead institution for the Nigeria project site. Topics covered included (1) an overview of the WAC-EID research; (2) overview of infection prevention and control; (3) safety in animal handling and restraint, sample collection, and processing; (4) safety in field studies including rodent, bird and bat handling; (5) safety practices in the collection of mosquito and other arthropod vectors; (6) personal protective equipment training (disinfection, donning and doffing); and (7) safety in sample collection, labeling, and transportation. The program was executed using a mixed method of slide presentations, practical hands-on sessions, and video demonstrations. Pre- and post-course evaluation assessments and evaluation measures were used to assess training. Results: A total of 48 trainees participated in this training, with 12 (25%), 16 (33.3%), 14 (29.2%), 6 (12.5%) categorized as ornithology, entomology, mammalogy, and clinical interest groups, respectively. The pass rate for the pre-test was 29.4%, while for the post-test, it was 57.1%, or a 28% improvement. 88.6% of the trainees rated the training as relevant to them. Conclusion: Didactic and hands-on biosafety training is relevant in this era of zoonotic epidemics and pandemic preparedness. During this training program, there was a clear demonstration of knowledge transfer that can change the current practices of participants and improve the safety of infectious diseases research. Keywords: biosafety, One Health, pandemic, training, biological safety.
- 27 March 2023
- Published by Veterinary World in International Journal of One Health
- Vol. 9 (1) , 10-14
Open AccessOne Health epidemic preparedness: Biosafety quality improvement training in Nigeria
Background and Aim: One of the key components of the O ne Health approach to epidemic preparedness is raising awareness and increasing the knowledge of emerging infectious diseases, prevention, and risk reduction. However, related research can involve significant risks to biosafety and biosecurity. For this purpose, we organized a multidisciplinary biosafety hands-on workshop to inform and increase the knowledge of infectious diseases and risk mitigation. This study aimed to describe the process and outcome of a hands-on biosafety training program using a One Health a pproach across a multidisciplinary and multi-specialty group in Nigeria. Materials and Methods: A face-to-face hands-on training for 48 participants was organized by the West African Center for Emerging Infectious Diseases (WAC-EID) at the Jos University Teaching Hospital, serving as a lead institution for the Nigeria project site. Topics covered included (1) an overview of the WAC-EID research; (2) overview of infection prevention and control; (3) safety in animal handling and restraint, sample collection, and processing; (4) safety in field studies including rodent, bird and bat handling; (5) safety practices in the collection of mosquito and other arthropod vectors; (6) personal protective equipment training (disinfection, donning and doffing); and (7) safety in sample collection, labeling, and transportation. The program was executed using a mixed method of slide presentations, practical hands-on sessions, and video demonstrations. Pre- and post-course evaluation assessments and evaluation measures were used to assess training. Results: A total of 48 trainees participated in this training, with 12 (25%), 16 (33.3%), 14 (29.2%), 6 (12.5%) categorized as ornithology, entomology, mammalogy, and clinical interest groups, respectively. The pass rate for the pre-test was 29.4%, while for the post-test, it was 57.1%, or a 28% improvement. 88.6% of the trainees rated the training as relevant to them. Conclusion: Didactic and hands-on biosafety training is relevant in this era of zoonotic epidemics and pandemic preparedness. During this training program, there was a clear demonstration of knowledge transfer that can change the current practices of participants and improve the safety of infectious diseases research. Keywords: biosafety, One Health, pandemic, training, biological safety.
- Open Access
- 31 January 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (1) , e0001313
A multicenter survey of asymptomatic cryptococcal antigenemia among patients with advanced HIV disease in Nigeria
As of 2018, cryptococcal antigen (CrAg) screening in patients with advanced human immunodeficiency virus (HIV) disease (AHD) was not routinely implemented in Nigeria despite being recommended in the national HIV treatment guidelines. Our aim was to determine the prevalence and risk factors for asymptomatic cryptococcal antigenemia in adult people living with HIV (PLHIV) in Nigeria to advocate for the implementation of routine CrAg screening. A descriptive cross-sectional study and CrAg screening of consecutive adult PLHIV with CD4 counts ≤200 cells/μL was conducted from April 2018 to April 2019 at HIV clinics in eleven tertiary hospitals spread across Nigeria’s six geopolitical regions. Prevalence of asymptomatic cryptococcal antigenemia was estimated by facility and geopolitical zone. Logistic regression was conducted to identify risk factors for cryptococcal antigenemia. In total, 1,114 patients with AHD were screened. The overall prevalence of asymptomatic cryptococcal antigenemia was 3.9% with wide variation across facilities (range: 0/75 [0%]– 15/122 [12.3%]) and geopolitical zones (range: 0/75 [0%]–19/279 [6.8%]). Prevalence of antigenemia was highest in the South-West (19/279 [6.8%]) and lowest in the North-East (0/75 [0%]). Prevalence was 5.2% (26/512) and 3.2% (18/561) in patients with CD4<100 and CD4 of 101–200, respectively. Of all patients with antigenemia, 50% were on antiretroviral therapy (ART) at the time of having a positive CrAg test. In adjusted analysis, cryptococcal antigenemia was significantly less in patients on ART and patients who had completed any formal education. The survey showed a high overall burden of cryptococcal antigenemia in Nigeria, with variable prevalence across geopolitical regions. We provided valuable evidence for implementing routine CrAg screening of AHD patients in Nigeria which has commenced in selected centres.
- 31 January 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (1) , e0001313
Open AccessA multicenter survey of asymptomatic cryptococcal antigenemia among patients with advanced HIV disease in Nigeria
As of 2018, cryptococcal antigen (CrAg) screening in patients with advanced human immunodeficiency virus (HIV) disease (AHD) was not routinely implemented in Nigeria despite being recommended in the national HIV treatment guidelines. Our aim was to determine the prevalence and risk factors for asymptomatic cryptococcal antigenemia in adult people living with HIV (PLHIV) in Nigeria to advocate for the implementation of routine CrAg screening. A descriptive cross-sectional study and CrAg screening of consecutive adult PLHIV with CD4 counts ≤200 cells/μL was conducted from April 2018 to April 2019 at HIV clinics in eleven tertiary hospitals spread across Nigeria’s six geopolitical regions. Prevalence of asymptomatic cryptococcal antigenemia was estimated by facility and geopolitical zone. Logistic regression was conducted to identify risk factors for cryptococcal antigenemia. In total, 1,114 patients with AHD were screened. The overall prevalence of asymptomatic cryptococcal antigenemia was 3.9% with wide variation across facilities (range: 0/75 [0%]– 15/122 [12.3%]) and geopolitical zones (range: 0/75 [0%]–19/279 [6.8%]). Prevalence of antigenemia was highest in the South-West (19/279 [6.8%]) and lowest in the North-East (0/75 [0%]). Prevalence was 5.2% (26/512) and 3.2% (18/561) in patients with CD4<100 and CD4 of 101–200, respectively. Of all patients with antigenemia, 50% were on antiretroviral therapy (ART) at the time of having a positive CrAg test. In adjusted analysis, cryptococcal antigenemia was significantly less in patients on ART and patients who had completed any formal education. The survey showed a high overall burden of cryptococcal antigenemia in Nigeria, with variable prevalence across geopolitical regions. We provided valuable evidence for implementing routine CrAg screening of AHD patients in Nigeria which has commenced in selected centres.
- Open Access
- 24 June 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (6) , e0000290
Epidemiological review of confirmed Lassa fever cases during 2016–2018, in Plateau State, North Central Nigeria
Lassa fever (LF) is endemic in West Africa and constitutes a significant public health concern due to its potential for epidemics and associated high mortality. The first reported case and management of Lassa fever in Plateau State occurred more than 50 years ago. We set out to undertake a three-year epidemiological review of LF cases in Plateau State, North Central Nigeria. This is a retrospective study of all confirmed LF cases in Plateau State between 2016 and 2018. Plateau state Lassa fever- Line list and patient case records were used to extract relevant data. Lassa PCR was carried out at the NCDC accredited Laboratory network. Data analysis was done using STATA version SE14.1. Forty-four persons (44) had confirmed LF over the examined period, 18 (41%) in 2016, 15 (34%) in 2017 and 11 (25%) in 2018. The mean age was 29.7±14.6 years and 53% were males. Sixty-six percent (66%) of the patients resided in rural areas. It affected all local government areas (LGA) in the state except Pankshin, Jos East and Kanke LGAs. Twenty-five percent (25%) of the cases occurred among underprivileged communities of Jos North and another 25% in rural dwellers of Langtang North. Fifty-nine percent (59%) of cases occurred during the 1st quarter, 27% the 2nd quarter and 18% the 3rd quarter of the year. The case fatality rate was 57%. LF is endemic in Plateau State. Prevention strategies must be sustained year round and target the youth, urban and rural underprivileged communities. There is also need for case management improvement to reduce mortality.
- 24 June 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (6) , e0000290
Open AccessEpidemiological review of confirmed Lassa fever cases during 2016–2018, in Plateau State, North Central Nigeria
Lassa fever (LF) is endemic in West Africa and constitutes a significant public health concern due to its potential for epidemics and associated high mortality. The first reported case and management of Lassa fever in Plateau State occurred more than 50 years ago. We set out to undertake a three-year epidemiological review of LF cases in Plateau State, North Central Nigeria. This is a retrospective study of all confirmed LF cases in Plateau State between 2016 and 2018. Plateau state Lassa fever- Line list and patient case records were used to extract relevant data. Lassa PCR was carried out at the NCDC accredited Laboratory network. Data analysis was done using STATA version SE14.1. Forty-four persons (44) had confirmed LF over the examined period, 18 (41%) in 2016, 15 (34%) in 2017 and 11 (25%) in 2018. The mean age was 29.7±14.6 years and 53% were males. Sixty-six percent (66%) of the patients resided in rural areas. It affected all local government areas (LGA) in the state except Pankshin, Jos East and Kanke LGAs. Twenty-five percent (25%) of the cases occurred among underprivileged communities of Jos North and another 25% in rural dwellers of Langtang North. Fifty-nine percent (59%) of cases occurred during the 1st quarter, 27% the 2nd quarter and 18% the 3rd quarter of the year. The case fatality rate was 57%. LF is endemic in Plateau State. Prevention strategies must be sustained year round and target the youth, urban and rural underprivileged communities. There is also need for case management improvement to reduce mortality.
- Open Access
- 6 January 2022
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 16 (1) , e0010089
A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever
Background: Only one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This recommendation is primarily based on evidence generated from a single clinical trial that was conducted more than 30 years ago–the methodology and results of which have recently come under scrutiny. The requirement for novel therapeutics and reassessment of ribavirin is therefore urgent. However, a significant amount of work now needs to be undertaken to ensure that future trials for LF can be conducted consistently and reliably to facilitate the efficient generation of evidence.Methodology: We convened a consultation group to establish the position of clinicians and researchers on the core components of future trials. A Core Eligibility Criteria (CEC), Core Case Definition (CCD), Core Outcome Set (COS) and Core Data Variables (CDV) were developed through the process of a multi-stakeholder consultation that took place using a modified-Delphi methodology.Results: A consensus position was achieved for each aspect of the framework, which accounts for the inclusion of pregnant women and children in future LF clinical trials. The framework consists of 8 core criteria, as well as additional considerations for trial protocols.Conclusions: This project represents the first step towards delineating the clinical development pathway for new Lassa fever therapeutics, following a period of 40 years without advancement. Future planned projects will bolster the work initiated here to continue the advancement of LF clinical research through a regionally-centred, collaborative methodology, with the aim of delineating a clear pathway through which LF clinical trials can progress efficiently and ensure sustainable investments are made in research capacity at a regional level.
- 6 January 2022
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 16 (1) , e0010089
Open AccessA standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever
Background: Only one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This recommendation is primarily based on evidence generated from a single clinical trial that was conducted more than 30 years ago–the methodology and results of which have recently come under scrutiny. The requirement for novel therapeutics and reassessment of ribavirin is therefore urgent. However, a significant amount of work now needs to be undertaken to ensure that future trials for LF can be conducted consistently and reliably to facilitate the efficient generation of evidence.Methodology: We convened a consultation group to establish the position of clinicians and researchers on the core components of future trials. A Core Eligibility Criteria (CEC), Core Case Definition (CCD), Core Outcome Set (COS) and Core Data Variables (CDV) were developed through the process of a multi-stakeholder consultation that took place using a modified-Delphi methodology.Results: A consensus position was achieved for each aspect of the framework, which accounts for the inclusion of pregnant women and children in future LF clinical trials. The framework consists of 8 core criteria, as well as additional considerations for trial protocols.Conclusions: This project represents the first step towards delineating the clinical development pathway for new Lassa fever therapeutics, following a period of 40 years without advancement. Future planned projects will bolster the work initiated here to continue the advancement of LF clinical research through a regionally-centred, collaborative methodology, with the aim of delineating a clear pathway through which LF clinical trials can progress efficiently and ensure sustainable investments are made in research capacity at a regional level.